Menu

Rothwell Figg Blog

Skip navigation Menu
  • Regulatory
  • Legal
  • News
  • About RFEM
  • Search

IPR

Random entry RSS

You are here:

  1. Home
  2. Tag Archives: IPR
  • Posted in:

    • Legal

    Immunex Loses Battle Over Institution of Follow-on IPR Petitions

    By Andrew Storaska and Jennifer P. Nock March 23, 2018 Comments are off

    Sanofi-Aventis U.S. LLC, Genzyme Corporation, and Regeneron Pharmaceuticals, Inc. recently scored a victory in their ongoing dispute over a...

    Read more

    Tagged with: District Court, Dupixent®, Follow-on petitions, Genzyme, Immunex, IPR, PTAB, Regeneron, Sanofi

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • Legal

    A Rare Successful Challenge of a Patent for a Method of Manufacturing Biologic Drugs

    By Aydin Harston March 12, 2018 Comments are off

    Biologic drugs are large molecules, such as therapeutic proteins, DNA vaccines, monoclonal antibodies, and fusion proteins, that are...

    Read more

    Tagged with: Amgen, Apotex, BLA, FDA, Federal Circuit, filgrastim, IPR, Neulasta®, Neupogen®, pegfilgrastim, PTAB

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • Legal

    Genentech’s Carter ’213 Patent Asserted and Challenged

    By Spencer Johnson March 5, 2018 Comments are off

    In October, we reported on a growing number of IPR challenges to Genentech’s U.S. Patent No. 6,407,213 (“the ʼ213 patent”) to...

    Read more

    Tagged with: BLA, Boehringer Ingelheim, BPCIA, Celltrion, District Court, Genentech, Herceptin®, IPR, Litigation, Mylan, Pfizer, Samsung Bioepsis, Teva, trastuzumab

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Sandoz’s Challenge to Two of AbbVie’s Humira® Patents Denied by PTAB

    By Monica Chin Kitts February 26, 2018 Comments are off

    Sandoz’s request for inter partes review (“IPR”) of U.S. Patent Numbers 9,512,216 (“the ’216 patent”) and 8,802,100 (“the...

    Read more

    Tagged with: AbbVie, Humira®, IPR, PTAB, Sandoz

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Celltrion and Teva File Declaratory Judgment Action Against Thirty-Seven Rituxan®-related Patents

    By Seth Cockrum January 16, 2018 Comments are off

    We previously reported that on January 11, 2018, Celltrion, Inc., Celltrion Healthcare, Co. Ltd. (collectively “Celltrion”), Teva...

    Read more

    Tagged with: Biogen, Celltrion, Genentech, Herceptin®, IPR, News, PTAB, Rituxan®, Rituximab, Roche, Teva, trastuzumab

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • News

    Celltrion and Teva File Declaratory Judgment Action Against Thirty–Eight Herceptin®-related Patents

    By Seth Cockrum January 15, 2018 Comments are off

    On January 11, 2018, Celltrion, Inc., Celltrion Healthcare, Co. Ltd. (collectively “Celltrion”), Teva Pharmaceuticals International...

    Read more

    Tagged with: BPCIA, Celltrion, Genentech, Herceptin®, IPR, News, Patent Dance, Roche, Teva, trastuzumab

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • Legal

    Standing Questioned Before the Federal Circuit in Momenta Pharms. v. Bristol-Myers Squibb Co.

    By Nicole DeAbrantes January 5, 2018 Comments are off

    On December 5, 2017, the Federal Circuit held oral argument in Momenta Pharmaceuticals, Inc. v. Bristol-Myers Squibb Company, 17-1694. The...

    Read more

    Tagged with: abatacept, Bristol-Myers Squibb, Federal Circuit, IPR, Momenta Pharmaceuticals, Orencia®, PTAB

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • Legal

    One of Three Pfizer IPR Petitions Instituted on Rituxan® Patents

    By Spencer Johnson November 28, 2017 Comments are off

    As we previously reported, Pfizer filed three IPR petitions against Biogen-owned patents claiming methods of treatment with rituximab in...

    Read more

    Tagged with: Biogen, Boehringer Ingelheim, Celltrion, IPR, Legal, Pfizer, PTAB, Rituxan®, Rituximab

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

  • Posted in:

    • Legal

    Humira®’s Wall of Patents Continues to Come Under Attack

    By Caitlin M. Wilmot November 13, 2017 Comments are off

    On November 6, 2017, Sandoz, Inc. filed its eighth inter partes review (“IPR”) against AbbVie Biotechnology Ltd. (“AbbVie”),...

    Read more

    Tagged with: AbbVie, Amgen, Boehringer Ingelheim, Coherus, Humira®, IPR, Legal, PTAB, Samsung Bioepsis, Sandoz

    http://twitter.com/share?text="[TITLE]&url=[PERMALINK]

    ShareEmail, Linked In, Twitter, Facebook, Google Plus

Pages

  • 1
  • 2
  • 3
  • 4
  • 5
  • Next

Featured Posts

  • Litigation Spotlight Update: The Infliximab (Remicade®) Litigation

    February 5, 2018

  • Litigation Spotlight Update: The Epoetin alfa (Epogen®) Litigation

    August 2, 2017

  • Litigation Spotlight Update: The Saga Continues: The Infliximab (Remicade®) Litigation

    June 12, 2017

Sign Up for Updates


Don’t worry. We don’t spam.

Thank you for subscribing.

Already subscribed.

Practice Contacts

  • E. Anthony Figg

  • Joseph A. Hynds

Popular Tags

AbbVie adalimumab Amgen Avastin® bevacizumab Biocon Biogen BPCIA Celltrion District Court EMA FDA Featured Federal Circuit Genentech Herceptin® Hospira Humira® Infliximab IPR Janssen Legal Litigation Mabthera Mylan Neulasta® News Notice Requirement Patent Dance pegfilgrastim Pfizer PTAB Regeneron Regulatory Remicade® Rituxan® Rituximab Roche Samsung Bioepsis Sandoz Sanofi Supreme Court Teva trastuzumab USPTO
Opinions expressed in articles on www.BiosimilarsIP.com are solely those of the author only and do not necessarily reflect the views of Rothwell Figg Ernst & Manbeck, P.C., its clients, or any of its respective affiliates. These materials are for general information purposes only and should not be taken as legal advice per the full disclaimer below.

Contact Us

Email Us
202.783.6040
Our Location

Find Out More

  • About Us
  • Results
  • Careers
  • Practices
  • Knowledge Center
  • Events
  • Professionals

Connect

  • Connect with Us on LinkedIn
  • Follow Us on Twitter
  • Like Us!

© 2017 Rothwell, Figg, Ernst & Manbeck, P.C. All Rights Reserved

  • Disclaimer
  • Privacy Policy
Back to Top